Andrew Dagis
Stanford University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Andrew Dagis.
The New England Journal of Medicine | 1993
Nelson J. Chao; Gerhard M. Schmidt; Joyce C. Niland; Michael D. Amylon; Andrew Dagis; Gwynn D. Long; Auayporn Nademanee; Robert S. Negrin; Margaret R. O'Donnell; Pablo Parker; Eileen Smith; David S. Snyder; Anthony S. Stein; Ruby M. Wong; Karl G. Blume; Stephen J. Forman
BACKGROUNDnAcute graft-versus-host disease (GVHD) following allogeneic bone marrow transplantation remains a serious problem. In a clinical trial, we tested the combination of cyclosporine and prednisone with and without methotrexate for the prevention of GVHD.nnnMETHODSnOne hundred fifty patients with either acute leukemia in first complete remission, chronic myelogenous leukemia in first chronic phase, or lymphoblastic lymphoma in first complete remission were enrolled in the study. All the patients were given fractionated total-body irradiation (1320 cGy) and etoposide (60 mg per kilogram of body weight) in preparation for transplantation, and received bone marrow from genotypically histocompatible donors. To prevent GVHD, they were randomly assigned to prophylactic treatment with either cyclosporine, methotrexate, and prednisone or cyclosporine and prednisone without methotrexate. All the patients received standardized supportive care after transplantation, including intravenous gamma globulin.nnnRESULTSnPatients receiving cyclosporine, methotrexate, and prednisone had a significantly lower incidence of acute GVHD of grades II to IV (9 percent) than those receiving cyclosporine and prednisone (23 percent, P = 0.02). Multivariate regression analysis demonstrated that an increased risk of acute GVHD was associated with an elevated serum creatinine concentration (P = 0.006) and treatment with cyclosporine and prednisone alone (P = 0.02). The lower incidence of acute GVHD was not associated with a higher rate of relapse of leukemia or lymphoma. There was no significant difference in disease-free survival at three years between the two treatment groups (64 percent with the three-drug regimen vs. 59 percent with the two-drug regimen, P = 0.57).nnnCONCLUSIONSnThe combination of cyclosporine, methotrexate, and prednisone was more effective in preventing acute GVHD of grades II to IV than was the combination of cyclosporine and prednisone without methotrexate.
Leukemia | 1999
David S. Snyder; Auayporn Nademanee; O’Donnell; Pablo Parker; Anthony S. Stein; Kim Margolin; George Somlo; Arturo Molina; Ricardo Spielberger; Ashwin Kashyap; Henry Fung; Marilyn L. Slovak; Andrew Dagis; Robert S. Negrin; Amylon; K. G. Blume; Stephen J. Forman
Between 1984 and 1997, 23 consecutive patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in first complete remission were treated with allogeneic bone marrow transplants from HLA-matched siblings. All patients but one were conditioned with fractionated total body irradiation (1320u2009cGy) and high-dose etoposide (60u2009mg/kg). One patient received high-dose cyclophosphamide instead of etoposide, and another patient received both drugs. Nine patients died following BMT, two from relapsed leukemia, and seven from transplant-related causes. The 3-year probabilities of disease-free survival and relapse are 65% and 12%, respectively. For patients transplanted after 1992, these probabilities are 81% (48–95%, 95% confidence interval) and 11% (2–50%), respectively. The relatively low relapse rate in this group of patients compared to published reports may reflect the enhanced anti-leukemic activity of etoposide in combination with FTBI compared to other conditioning regimens. The enhancement in overall survival for patients transplanted after 1992 may reflect improvements in supportive care, in particular, the prophylaxis of serious fungal and viral infections.
Biology of Blood and Marrow Transplantation | 1998
Eileen Smith; Irena Sniecinski; Andrew Dagis; Pablo Parker; David S. Snyder; Anthony S. Stein; Auayporn Nademanee; Margaret O’Donnell; Arturo Molina; Gerhard M. Schmidt; Daniel E. Stepan; Neena Kapoor; Joyce C. Niland; Stephen J. Forman
Extracorporeal photochemotherapy (EP) is a therapeutic approach to the treatment of drug-resistant graft-vs.-host disease (GVHD) that uses the known immunosuppressive and immunomodulatory effects of ultraviolet light. In 1990, we initiated a pilot study to evaluate the efficacy and safety of EP in patients with refractory GVHD. Between 1991 and 1996, six patients with acute grade IV liver GVHD, 12 patients with chronic following acute GVHD, and six patients with de novo chronic GVHD were treated with EP. All patients had failed to respond to conventional GVHD immunosuppressive drug therapy of cyclosporine and prednisone. The six patients with acute liver GVHD had also received antithymocyte globulin (ATG); therapy for chronic GVHD included thalidomide in eight patients, psoralen plus ultraviolet A in five patients, and ATG in two patients. All patients with acute liver GVHD had progressive liver failure with short survival despite frequent EP. The response rate with EP treatment was 3 of 6 for patients with de novo chronic GVHD and 3 of 12 for patients with chronic following acute GVHD. Three patients with bronchiolitis obliterans had either no response or no documented disease progression while undergoing EP. Side effects of EP were minor and included gastrointestinal upset frequently, catheter-related sepsis in four patients, increased red blood cell and platelet transfusion requirements in one patient, and leukopenia in two patients. EP was discontinued in three patients because of side effects, including GI upset in one patient and bone marrow suppression in two patients. Side effects were reversible with the discontinuation of EP. We were unable to correlate response to EP with the level of methoxypsoralen, number of lymphocytes treated, or pattern of pre- and posttreatment CD4/CD8 ratio. We concluded that EP has some efficacy in the treatment of drug-resistant chronic GVHD, with minor overall toxicity.
Biology of Blood and Marrow Transplantation | 1999
Maureen Ross; Gerhard M. Schmidt; Joyce C. Niland; Michael D. Amylon; Andrew Dagis; Gwynn D. Long; Auayporn Nademanee; Robert S. Negrin; Margaret R. O'Donnell; Pablo Parker; Eileen Smith; David S. Synder; Anthony S. Stein; Ruby M. Wong; Stephen J. Forman; Karl G. Blume; Nelson J. Chao
Graft-vs.-host disease (GVHD) is a major predictor of outcome following allogeneic bone marrow transplantation (BMT). For patients alive at day 100 after BMT, the presence or absence of chronic GVHD is one of the most important determinants of survival and quality of life. We wished to determine the effects on chronic GVHD of two regimens used for the prophylaxis of acute GVHD: cyclosporine, methotrexate, and prednisone (CSA/MTX/PSE) and cyclosporine and prednisone (CSA/PSE). One hundred forty-nine evaluable patients were entered into the acute GVHD study. As of 31 March 1997, 63 months after the last patient underwent BMT, the median survival time was 4.5 years (range 0.09-9.9). The incidence of chronic GVHD was independent of the prophylactic regimen (55 vs. 54%), and extensive chronic GVHD occurred in 25 and 24% of patients receiving CSA/MTX/PSE and CSA/PSE, respectively. Of note, the median Karnofsky performance status of both groups was 100% (range 70-100%), reflecting the low incidence of extensive chronic GVHD. Survival rates free of chronic GVHD were 52 vs. 42% (p = 0.29) for patients receiving CSA/MTX/PSE vs. CSA/PSE. The incidence of relapse was also similar in both groups of patients. These data suggest that the combinations of CSA/MTX/PSE and CSA/PSE result in comparable chronic GVHD-free survival without an increase in leukemic relapse.
Blood | 1997
Auayporn Nademanee; Arturo Molina; Margaret R. O'Donnell; Andrew Dagis; David S. Snyder; Pablo Parker; Anthony S. Stein; Eileen Smith; Ina Planas; Ashwin Kashyap; Ricardo Spielberger; Henry Fung; K.K. Wong; George Somlo; Kim Margolin; Warren Chow; Irena Sniecinski; Nayana Vora; Karl G. Blume; Joyce C. Niland; Stephen J. Forman
Biology of Blood and Marrow Transplantation | 1996
Nelson J. Chao; Pablo Parker; Joyce C. Niland; Ruby M. Wong; Andrew Dagis; Gwynn D. Long; Auayporn Nademanee; Robert S. Negrin; David S. Snyder; Hu Ww; Gould Ka; D.K. Tierney; Zwingenberger K; Stephen J. Forman; K. G. Blume
Blood | 2007
Vinod Pullarkat; Suzette Blanchard; Bernard Tegtmeier; Andrew Dagis; Kathryn Patane; James I. Ito; Stephen J. Forman
Archive | 2013
Bihong T. Chen; A. Orlando Ortiz; Andrew Dagis; Cheryl Torricelli; Pablo Parker; Harry Openshaw
Archive | 2013
Christine White; Andrew Raubitschek; Eileen Smith; David S. Snyder; Ricardo Spielberger; Margaret R. O'Donnell; Pablo Parker; Leslie Popplewell; Vinod Pullarkat; Dave Yamauchi; Anne-Line Anderson; Peter Falk; Amrita Krishnan; Mark Kirschbaum; Neil Kogut; Auayporn Nademanee; Stephen J. Forman; Arturo Molina; Henry Fung; David D. Smith; Andrew Dagis
Archive | 2010
Stephen J. Forman; Kim Margolin; Warren Chow; Irena Sniecinski; Rathin Neeta Vora; Karl G. Blume; Eileen Pazderka Smith; Ashwin Kashyap; Ricardo Spielberger; H. S. Fung; Auayporn Nademanee; Arturo Molina; Margaret R. O'Donnell; Andrew Dagis; David S. Snyder